39results about "Tumor specific antigens" patented technology

Lung cancer remains the leading cause of cancer-related deaths in the world. Despite the fact that introduction of immune checkpoint inhibitors (ICIs) led to a major advancement in lung cancer treatment, disease prognosis continues to remain low and a significant proportion of patients do not respond to such therapies. Cancer vaccines could potentially provide a complementary approach to boost antitumor immunity and act synergistically with ICIs. Novel tumor antigens shared by a large proportion of lung tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

The present invention provides a T-cell receptor (TCR) that binds to an immunogenic peptide when the peptide is presented by the major histocompatibility complex (MHC).

The invention is directed to methods for determining antigen-specific T cells generally and to T cell receptors which bind an epitope of the Wilms' tumor antigen-1 (WT1) protein specifically. The disclosure also provides polynucleotides encoding the TCRs, engineered cells exogenously expressing the TCRs, and methods of making and using the TCRs and / or cells expressing the TCRs.

The present invention relates to combinations of host cells expression antigen binding proteins that specifically bind to a tumor expressed Preferentially Expressed Antigen of Melanoma (PRAME) antigenic peptide in a complex with MHC, and mRNAs encoding PRAME antigenic peptides. The invention further relates to combined TCR-T / mRNA therapy employing said mRNAs and host cells. In particular, a combined TCR-T / mRNA therapy is provided for use in cancer treatment.

The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.

Described herein are methods and compositions for isolating cancer cells using positively charged surfaces, such as beads, microparticles, and capillary tubes. The methods and compositions for isolation can be used in cancer diagnosis, treatment, and therapeutic preparation.

In particular, the present invention provides a fusion protein useful in the treatment and prevention of cancer, especially melanoma, and especially cutaneous melanoma and uveal melanoma. [Solution] A fusion protein is provided comprising six antigenic polypeptides (a) to (f), wherein each antigenic polypeptide (a) to (f) has an immunogenic fragment of a specific amino acid sequence or a variant thereof.

The present invention provides synthetic polypeptides comprising an annexin V protein, or a functional portion or fragment or variant thereof, conjugated to a tumor antigen, or a functional portion or fragment or variant thereof. The invention further provides methods for making said synthetic polypeptides and their use in the treatment of proliferative diseases such as cancer and tumors originating therefrom.

In various aspects and embodiments, this disclosure provides artificial antigen-presenting cells (aAPCs) suitable for parenteral administration for immunotherapy. In various embodiments, aAPCs effectively activate or inhibit target T cells, including CD8+ or CD4+ T cells, in vivo. The aAPCs according to this disclosure provide a storage-stable nanoparticle platform for immunotherapy. In various embodiments, the storage-stable nanoparticle platform controls characteristics such as particle size and particle chemistry, ligand design and ligand density, and aAPC aggregation tendency.

Provided are immunogenic agents and compositions tailored to induce immunity against hERV expression products in a high percentage of cancer patients as well. Also provided are methods for immune induction against cancer cells

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccincation strategy.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.

The present invention relates to tumor antigens or cancer antigens, particularly amino acid sequences and nucleic acid sequences, which may be used in cancer immunotherapy. In particular, the present invention relates to artificial nucleic acids, preferably RNA, comprising at least one coding sequence encoding at least one tumor antigen or cancer antigen. The tumor antigen or cancer antigen is Peptides or proteins encoded by small open reading frames (smORFs) of long non-coding RNA (IncRNA), or The fragment or variant thereof, At least one antigenic peptide selected from or derived therefrom, and / or Tumor neoantigen peptides or proteins, or The fragment or variant thereof, at least one antigenic peptide selected from or derived therefrom The invention provides a pharmaceutical composition comprising or consisting of the artificial nucleic acid, preferably formulated within a lipid-based carrier. It also provides a method for treating or preventing a disease, disorder, or condition, and medical applications for treating or preventing cancer in particular (such as NSCLC, HNSCC, or melanoma).

An mRNA, an mRNA vaccine formulation, and a preparation method and use thereof are provided. An amino acid sequence of the mRNA is set forth in SEQ ID NO: 2. Studies have demonstrated that the mRNA vaccine formulation prepared from the mRNA having the amino acid sequence set forth in SEQ ID NO: 2 can effectively stimulate dendritic cell maturation and secretion of pro-inflammatory cytokines, thereby activating effector T cells to kill prostate cancer cells. A preparation method of the mRNA vaccine formulation is simple and suitable for industrial-scale production. By using lipid nanoparticles (LNPs) as a carrier, the mRNA vaccine formulation achieves high encapsulation efficiency, enabling robust induction of immune responses in vivo with high immunogenicity.

The present invention provides methods for increasing the sensitivity of tumor cells to a TCR-engineered T cells (TCR-T) therapy comprising genetically modifying the tumor cells to express an haplotype, for example an HLA haplotype, different from the haplotype endogenous to the tumor cells.

Provided herein is DNA vaccine and composition comprising PD1-based TWIST1. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine and an immune checkpoint inhibitor.

The present invention is directed to the development and use of novel photocrosslinking activity-based probes (ABPs). Specifically, ubiquitin-charged E2 conjugating enzymes are engineered and shown to be effective ABPs for RING ubiquitin E1 and E3 ligases and deubiquitinating enzymes.

Nucleic acid molecules comprising a heterologous promoter and an open reading frame encoding a T cell receptor (TCR) alpha chain comprising a CDR-A3 of SEQ ID NO: 3 and an open reading frame encoding a TCR beta chain comprising a CDR-B3 of SEQ ID NO: 4 are provided. Isolated populations of T cells and compositions comprising the nucleic acid molecules as well as methods of treating cancer are also provided.

The present disclosure provides isolated peptides derived from human T-lymphotropic virus type 1 (HTLV-1), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides methods and systems for identifying immunogenic virus-derived peptides.

This disclosure relates to targeting moieties, such as peptides and antibodies, that can bind to DLL3. The disclosure also provides targeted constructs that may include a targeting moiety conjugated to a chelating agent for cargo association via an optional linker. Methods for constructing the constructs and formulations thereof are also provided. Methods for using the constructs and / or formulations to treat a target, for example, to treat or prevent cancer, are also described.

The purpose of the present invention is to provide a means for selecting subject-derived neoantigens. The above problem is solved by providing a method for selecting a subject-derived neoantigen, said method comprising: a step of acquiring sequence data of a normal cell and a cancer cell derived from a subject, a step of identifying a gene having a genetic mutation specific to the cancer cell, and a step of identifying a peptide based on a wild-type gene corresponding to the gene having the genetic mutation specific to the cancer cell from a major histocompatibility complex (MHC)-presented peptide database, wherein the genetic mutation is a missense mutation, and the peptide based on the wild-type gene corresponding to the gene having the genetic mutation has a wild-type amino acid corresponding to the position of an amino acid mutation due to the genetic mutation.

Antigenic compositions comprising one or more labyrinthin-derived peptides are described herein. In some embodiment, each peptide of the antigenic composition comprises a T-cell epitope and / or a B-cell epitope. In other aspects, the present disclosure provides, e.g., vaccine compositions comprising tin antigenic composition disclosed herein, including kits, medicines, and compositions (such as pharmaceutical compositions and unit dosages) thereof. Also provided are methods of using the compositions disclosed herein, such as methods of treatment thereof and methods of producing antibodies, and antibody compositions thereof, against the one or more labyrinthin-derived peptides or a portion thereof.

Disclosed herein are vectors that include alphavirus-based expression platforms. Also disclosed are methods associated with the alphavirus-based expression platforms and co-administration of an inhibitor of Type I interferon signaling.

Fusion molecules comprising an immune cell engager and a cytokine are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods of using, the fusion molecules.

Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also describe

Disclosed herein is a method for diagnosing a mycobacterial infection in a subject. The method comprises performing acetonitrile fractionation of a subject sample to deplete depleted in high molecular weight proteins. The sample is enzymatically digested and analyzed with liquid chromatography tandem mass spectrometry (LC-MS / MS) and bottom-up proteomic analysis to identify a plurality of sample peptides. The sample is then analyzed with a classifier algorithm and a PW species identification score (PWsp) is generated by dividing the number of single and multi-peptide combinations that identify a specific mycobacterium species by the total number of peptide combinations specific for any mycobacteria. A higher PWsp for a given species of mycobacterium indicates a higher likelihood the subject has an infection of that species. This method provides an efficient and accurate way of diagnosing mycobacterial infections in subjects.

Provided is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 59, or a pharmaceutically acceptable salt thereof.

The present invention relates to: a fusion protein comprising a peptide antigen and a human thioredoxin protein linked to the N-terminus, the C-terminus or both of the peptide antigen, wherein all cysteine residues in the amino acid sequence of the human thioredoxin protein are substituted with non-cysteine residues; a nucleic acid molecule encoding the fusion protein; an expression vector comprising the nucleic acid molecule; a cell transformed with the expression vector; and a composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.